VKTX Viking Therapeutics, Inc. Insider Trading

CCO Neil Aubuchon buys 4,475 shares of VKTX at $33.50; first position, stock -17.6% from 52-week high.

Neil Aubuchon, Chief Commercial Officer, initiated a first position in Viking Therapeutics by purchasing 4,475 shares at $33.50 on 2026-03-10, with no prior holdings. The company posted a net income of $-90,787,000.00 and $0.00 quarterly revenue, indicating it remains in development or early commercialization phase. The stock is currently trading at $34.66, modestly above the purchase price, and sits 17.6% below its 52-week high of $42.09 after a -7.6% decline over the past 90 days. This buy by the Chief Commercial Officer—a role typically focused on sales, market access, and revenue generation—is noteworthy given the company's lack of demonstrated revenue and large operating losses, suggesting either confidence in near-term commercialization or alignment incentive rather than a response to price weakness.

CEO Lian Brian sells 233,409 shares for $7.7M at blended $32.96, reducing stake 8.5% at near 52-week highs.

Lian Brian, President & CEO of Viking Therapeutics (VKTX), executed 4 separate sales totaling 233,409 shares for $7,692,120.64 on 2026-01-05, with individual transaction prices ranging from $32.29 to $35.07 and a blended average price of $32.96. This sale reduced his post-transaction holdings to 2,499,291 shares from 2,732,700 shares, representing an 8.5% reduction in his stake. The timing occurs when VKTX trades at $32.14, near its 52-week high of $42.89 (the current price is only 25.1% below the 52-week peak), and follows a 16.6% decline over the prior 30 days. His prior 4 sales at VKTX were all well-timed at the 90-day mark, with three showing declines of -22.7%, -21.5%, and -6.6%, and one showing a minor gain of +3.6%, establishing a clear pattern of sales preceding downturns. The company remains unprofitable with a net loss of $-90,787,000 for the latest quarter and zero revenue, and the CEO's sustained pattern of well-timed sells at this ticker warrants close monitoring of near-term price action.

VKTX COO Mancini sells 57,661 shares for $1.9M as stock falls -25.1% from 52-week high

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, executed 4 separate sales totaling 57,661 shares for $1,901,405.31 on 2026-01-05, reducing her holdings by 12.4% to 409,190 shares post-transaction. The blended average price of $32.98 occurs as the stock trades at $32.14, down -25.1% from its 52-week high of $42.89 and down -16.6% over the prior 30 days. Her same-ticker history at VKTX shows mixed timing outcomes: three of five prior sales were well-timed at the 90-day mark (stock subsequently fell), though two prior sales on 2024-07-30 saw subsequent 30-day and 90-day gains. The company posted $-90,787,000 net loss most recently with zero revenue, suggesting ongoing operational strain. The scale of this insider reduction (57.7K shares) warrants attention given the company's unprofitable status and the stock's recent retreat, though the transaction timing relative to price action does not yet constitute a clear reversal signal.

CFO Greg Zante sells 57,661 shares of VKTX for $1,896,969.39 on 2026-01-05; 5 of 5 prior VKTX sales well-timed with negative 90-day returns averaging -51.6%.

On 2026-01-05, Greg Zante (CFO) executed four separate sales totaling 57,661 shares for $1,896,969.39, reducing his holdings by 23.3% to 189,891 shares at a blended average price of $32.90. His prior trade history at VKTX is notably consistent: all five prior sales achieved well-timed exits, with 90-day average returns of -51.6% (ranging from -47.0% to -55.2%), indicating the stock declined meaningfully after each prior sale. The company is unprofitable ($-90,787,000.00 net income) with zero revenue in the latest quarter and a $3.6B market cap, providing fundamental context for a CFO's large discretionary sale. The current stock price ($32.14) is -25.1% from its 52-week high of $42.89 and down -16.6% over 30 days, positioning this sale in an already-declining price environment where the insider's decision to liquidate a meaningful fraction of holdings merits investor scrutiny.

VKTX CEO Lian Brian sold 38,989 shares at $35.01; stock now $34.93, down 55.2% from $78.03 high. All 5 prior VKTX sales were well-timed (negative 90d returns).

Lian Brian sold 38,989 shares (39.0K shares) on 2025-10-28 at $35.01, reducing holdings from 2.46M to 2.42M shares. The company is unprofitable with net income of $-90,787,000.00 and $0.00 revenue in the latest quarter. Notably, Brian's prior 5 trades at VKTX show a 100% well-timed pattern at the 90-day mark, with all sales followed by negative returns: his July 2025 sale saw 90d return of -1.6%, and his four sales in early 2025 and late 2024 were followed by 90d declines ranging from -41.7% to -47.8%. This current sale at $35.01 occurred when the stock was already down 55.2% from its 52-week high of $78.03 and up 36.6% over the prior 30 days, presenting a factual test of his historical timing pattern at this specific ticker.

Director Rowland Charles A Jr sold 60,000 shares of VKTX at $35.57 (2.1M), reducing holdings 66.7%; stock down 55.2% from $78.03 high.

Director Rowland sold 60,000 shares (60.0K shares) at $35.57 on 2025-10-27, reducing his stake by 66.7% from 90,000 shares (90.0K shares) to 30,000 shares (30.0K shares). The transaction occurred when the stock was trading at $35.57, which is 55.2% below the 52-week high of $78.03, and the company reported net income of $-90,787,000.00 ($-90.8M) with $0.00 revenue in its latest quarter. Rowland's cross-ticker track record shows strong historical performance (2 prior buys with avg 90d return of +1731.4% and a 100% win rate), yet this represents a substantial reduction in his Viking position rather than accumulation, occurring during a period of significant stock depreciation and ongoing operating losses.

VKTX CEO Brian Lian sells 26,889 shares at $27.80; prior 5 sales at ticker all well-timed with negative 90d returns.

CEO Brian Lian sold 26,889 shares at $27.80 on 2025-07-03, reducing holdings by 1.1% to 2,388,014 shares. This sale occurs as VKTX trades 63.9% below its 52-week high of $78.03 despite a recent 5.9% 30-day gain. Notably, all five of Lian's prior sales at VKTX have been well-timed, with each followed by 90-day negative returns ranging from -41.1% to -47.8%, establishing a 100% track record of selling before subsequent declines at this specific ticker. The company generated zero revenue in the latest quarter with a net loss of $-45,629,000, underscoring the stage of operations where fundamentals remain unprofitable. This pattern of consistent sell-timing at VKTX combined with the transaction during a significant drawdown from peak valuations warrants attention to whether current valuations have appropriately reflected execution risks in this clinical-stage asset.

Viking Therapeutics Director Rouan bought 1,240 shares at $24.15 on 2025-03-31 ($29,942.78); stock now -68.7% from 52-week high of $82.00

Rouan Sarah Kathryn, a Director of Viking Therapeutics, purchased 1,240 shares at $24.15 on 2025-03-31, establishing an initial position of 1,240 shares valued at $29,942.78. The transaction occurred at a significant discount to the stock's 52-week high of $82.00, with the stock currently trading -68.7% below that peak and down -37.6% over the past 90 days. The company is unprofitable with net income of $-24,940,000.00 for the most recent full fiscal year and $0.00 in latest quarter revenue. The purchase represents a board member's capital deployment in a clinical-stage biotech company amid a substantial drawdown from its recent highs, though the limited transaction size and new holder status provide limited evidence of conviction magnitude.

COO Marianna Mancini sold 54,215 shares for $2,317,599.12 at avg $42.75 on 2025-01-06; stock now -55.0% from 52-week high.

Mancini executed 2 separate sales totaling 54,215 shares for $2,317,599.12, reducing her holdings by 12.7% from 428,349 to 374,134 shares. The timing context is relevant: her prior 5 same-ticker sales at VKTX produced mixed returns (3 of 5 well-timed at the 90-day mark), but her cross-ticker track record shows a 71.43% well-timed rate across 7 prior sells with a -11.4% average 90-day return. However, the company context is material—VKTX is unprofitable (net income $-24,940,000.00 in the latest quarter), generated zero revenue in the latest quarter, and the stock has fallen -55.0% from its 52-week high of $94.50 and -36.2% over the past 90 days. The sale prices of $42.69 and $43.32 occurred as the stock approached its current $42.53 price, placing the sales near the lower end of recent trading. This transaction reflects a meaningful reduction in equity exposure by a senior executive during a period of significant drawdown and ongoing operating losses.

CFO Greg Zante sells 50,309 shares at blended $42.75; stock down -55.0% from 52-week high of $94.50.

Greg Zante, CFO of Viking Therapeutics (VKTX), executed 2 separate sales totaling 50,309 shares for $2,150,594.66 on 2025-01-06 at an average price of $42.75. The sale represents a -23.3% reduction of his post-transaction holdings (165,259 shares remain). The stock currently trades at $42.53, down -55.0% from its 52-week high of $94.50 and -36.2% over the past 90 days, suggesting this sale occurred during a sustained downtrend. At the same-ticker level, Zante's five prior sells at VKTX (all on 2024-10-28) each showed negative 30-day returns ranging from -26.9% to -33.1%, indicating his recent selling activity has coincided with further declines. The company reported zero revenue in the latest quarter and a net loss of $24,940,000, underscoring fundamental operational challenges that investors should monitor.